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Toll like receptors (TLRs) are a family of pattern recognition receptors that play a central
role in the innate immune response. These receptors are expressed on a wide variety of
immune and non-immune cells, and they help shape the immune response to infection
and injury through the recognition of pathogen-associated molecular patterns (PAMPs)
as well as endogenous damage-associated molecular patterns (DAMPs). Accumulating
evidence suggests that, in addition to regulating mature effector immune cells, TLRs
can influence the immune response from the level of the hematopoietic stem cell
(HSC). HSCs express TLRs, and exposure to TLR ligands influences the cycling,
differentiation, and function of HSCs, with chronic TLR stimulation leading to impairment
of normal HSC repopulating activity. Moreover, enhanced TLR expression and signaling
is associated with myelodysplastic syndromes (MDS), a heterogenous group of HSC
disorders characterized by ineffective hematopoiesis and a high risk of transformation
to acute leukemias. In this review, we will discuss the role of TLR signaling in the
pathogenesis of MDS, focusing on the known direct and indirect effects of this type of
signaling on HSCs, themechanisms of TLR signaling upregulation inMDS, the changes in
TLR expression with disease progression, and the therapeutic implications for modulating
TLR signaling in the treatment of MDS.
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INTRODUCTION
The TLRs are a family of pattern recognition receptors that recognize foreign pathogen-associated
molecular patterns (PAMPs) as well as endogenous byproducts of cellular damage (so called
“damage-associated molecular patterns,” or DAMPs) (1, 2), and play a central role in the innate
immune response to infections and tissue injury (3–6). TLR signaling regulates not only mature
effector cells of the immune system, but also influences hematopoietic stem cells (HSCs) through
both cell-autonomous and cell non-autonomous mechanisms (7–9). Furthermore, chronic TLR
signaling can impair normal HSC function (10). In patients with myelodysplastic syndromes
(MDS), TLR signaling is enhanced via a combination of genetic and epigenetic events that influence
multiple components of the TLR signaling pathway. This enhanced signaling is particularly
notable in lower-risk MDS, and contributes to the marked cell death and ineffective hematopoiesis
characteristic of this disease (11). Here, we focus on the role of TLR signaling in MDS, highlighting
the mechanisms and implications of TLR upregulation, the differences between lower- and
Paracatu and Schuettpelz TLR Signaling in MDS
higher-risk disease, and the therapeutic opportunities for
targeting TLR signaling in the treatment of MDS.
TLR Signaling Regulates Hematopoietic
Stem and Progenitor Cell Function
The TLR family is comprised of 10 members in humans (TLR1-
TLR10) (5, 12–15), and 12 members in mouse (TLR1- TLR9,
and TLR11-TLR13) (16). TLRs are expressed on a variety of
hematopoietic cell types, such as dendritic cells, macrophages,
and lymphocytes, as well as non-hematopoietic cells such as
endothelium and epithelium (17–20), and can be found at the
cell surface (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11)
or within endosomes (TLR3, TLR7, TLR8, and TLR9). TLRs
largely function as homodimers, with the exception of TLR2,
which heterodimerizes with either TLR1 or TLR6 (21–23).
With the exception of TLR3, which signals via the adaptor
TIR-domain-containing adaptor-inducing interferon-β (TRIF)
(24, 25), the TLRs utilize the intracellular signaling adaptor
myeloid differentiation primary response gene 88 (MyD88) (26).
MyD88 is recruited to activated TLRs, and this is followed
by recruitment of members of the serine-threonine kinase
interleukin-1 receptor-associated kinase (IRAK) family (IRAK4,
IRAK1, and IRAK2), forming the so-called “Myddosome.” (27–
29) Activated IRAK1 then promotes the activity of the E3
ubiquitin ligase tumor necrosis factor (TNF) R-associated factor
6 (TRAF6), which in turn activates transforming growth factor
beta-activated kinase 1 (TAK1) leading to stimulation of mitogen
activated protein kinase (MAPK) and nuclear factor k-light-
chain-enhancer of activated B cells (NF-kB) pathways and
the production of proinflammatory cytokines (30). Endosomal
TLRs (TLR3, TLR7, TLR8, and TLR9) act via the Myddosome
and TRAF6 to activate IFR7 and promote type I interferon
production. TRIF-dependent TLR signaling, utilized by TLR3
and, in part, TLR4, involves the binding of TRIF to TRAF3, which
then recruits TBK1 and IKKε thereby stimulating IRF3 and also
promoting the production of type I interferons (31–34).
In addition to regulating mature immune effector cells,
TLRs are expressed on more primitive hematopoietic stem
and progenitor cells (HSPCs) (7, 20, 35, 36), and even in
the absence of overt infection or injury, signaling through
the TLRs influences the differentiation, and function of
HSPCs. Proinflammatory signals, including TLR4-MyD88-NF-
kB activation, are required for HSC specification in both
zebrafish and mouse embryos (37, 38). Thereafter, TLR signaling
continues to regulate HSCs, as the bone marrow from mice
deficient in TLR signaling (Tlr2−/−, Tlr4−/−, Tlr9−/−, and
MyD88−/− mice) display enhanced repopulating activity in
competitive transplantation experiments (39, 40). Conversely,
chronic exposure to TLR ligands is associated with a loss
of normal HSC function. Persistent exposure of mice to the
TLR4 ligand LPS, for example, is associated with an expansion
of immunophenotypic HSCs, but a loss of HSC repopulating
function in transplantation experiments (10). Similarly, we
recently demonstrated that treatment of mice with the TLR1/2
ligand PAM3CSK4 expands immunophenotypic HSCs in both
the bone marrow and spleen, but reduces their repopulating
activity (8). Studies in chimeric mouse and in vitro models
suggest that these effects of TLR ligands on HSCs are mediated
by both direct (cell autonomous) and indirect (cell non-
autonomous) mechanisms. Supporting a direct effect of TLR
signaling on HSCs, for example, TLR stimulation via LPS or
PAM3CSK4 leads to proliferation and myeloid differentiation
of sorted HSPCs (Lineage- c-Kit+ Sca-1+ cells) in culture (7),
and purified HSPCs from wild-type mice transplanted into TLR-
deficient (Tlr2−/−, Tlr4−/−, or MyD88−/−) recipients (thus
minimizing indirect effects of TLR stimulation) differentiate into
macrophages upon treatment with TLR ligands (9). Takizawa
et al. (41) used chimericmice (Tlr4−/− andWT cells transplanted
into Tlr4−/− recipients) to show that LPS directly stimulates
HSC proliferation and impairs HSC self-renewal. Further, they
found that the LPS-induced loss of HSC self-renewal is TRIF-,
and not MyD88-, dependent, and is mediated by the production
of reactive oxygen species (ROS) and activation of p38 MAPK
(41). Zhang et al. (42) similarly showed that LPS-induced loss
HSC self-renewal is TRIF-dependent, and further highlighted
the differential effects of TRIF- and MYD88- dependent TLR4
signaling on HSPCs. While TRIF-mediated signaling accounts
for HSC expansion and loss of self-renewal in response to LPS,
MYD88- dependent signaling largely accounts for LPS-induced
myelosuppression via impaired differentiation and increased
death of myeloid progenitors (42). Our own studies using
chimeric mice treated with the TLR1/2 agonist PAM3CSK4
showed that while the loss of HSC function in response to
this type of stimulation is largely cell non-autonomous, direct
signaling does contribute to the expansion of immunophenotypic
HSCs (8). Thus, multiple TLRs can influence HSCs, both via
direct and indirect mechanisms.
TLR Expression and Signaling Is Increased
in Patients With Myelodysplastic
Syndromes (MDS), and Is Associated With
Disease Severity
The myelodysplastic syndromes (MDS) are a group of
hematopoietic stem cell disorders characterized by abnormal
hematopoiesis and a high risk of transformation to acute myeloid
leukemia (AML) (43, 44). There are ∼10,000 new cases of MDS
per year in the US, and the incidence increases with age (45).
MDS is rare in children and young adults, though it may occur
in these populations in association with inherited bone marrow
failure syndromes (46, 47). Patients with MDS suffer from
cytopenias, requiring supportive care (e.g., red blood cell and
platelet transfusions), and risk life-threatening consequences of
these cytopenias such as infections and bleeding. In addition,
about 30% of patients with MDS will progress to develop AML
(48). The prognosis of patients with MDS is determined using
the revised International Prognostic Scoring System (IPSS-R),
which considers the degree of cytopenias, bone marrow blast
percentage, and cytogenetic abnormalities (49). This score is
used to place patients into lower- and higher-risk categories,
and helps to inform their treatment. Depending on the age
of the patient, risk category, and other comorbid factors, the
treatment options include supportive care, hypomethylating
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agents, immunomodulatory drugs, and allogeneic hematopoietic
stem cell transplantation (50). Stem cell transplantation is
the only curative option, however this is often not feasible
due to patient age or other comorbid factors (51). Thus, new
therapies are needed. As discussed below, targeting of innate
immune signaling, and particularly TLRs, is an attractive new
therapeutic approach.
The pathogenesis of MDS is thought to involve a combination
of genetic mutations (particularly involving genes that regulate
RNA splicing or influence the epigenetic landscape, in addition
to variety of other oncogenes, and tumor suppressors) (52–
55), which may be induced or selected for by genotoxic insults,
inflammatory conditions, and/or aging, and hyper-activation of
innate immune signaling pathways as a result of these genetic and
epigenetic changes that contribute to HSPC senescence, impaired
differentiation and cellular death (56–59). In lower-risk MDS,
intact DNA damage checkpoints and pro-death signals lead to
the prominent intramedullary cell death characteristic of lower-
risk disease (60, 61). In contrast, the presence of mutations that
confer resistance to these damage checkpoints and pro-death
signals is characteristic of higher-risk MDS with an accelerating
clonal expansion and increased risk of transformation to acute
leukemia (62, 63). Notably, recent studies on the clonal evolution
of MDS suggest that in many cases, disease progression is non-
linear, with diverse subclones evolving in a parallel fashion to give
rise individually to the development of MDS and secondary AML
(62, 64, 65).
Regarding the contribution of hyper-activated innate immune
signaling, numerous studies have shown that TLR signaling
is enhanced in the CD34+ HSPCs of patients with MDS,
with multiple components of the pathway (TLRs themselves
or downstream effectors) either overexpressed or aberrantly
activated compared to healthy controls (66–70). Wei et al. (69)
profiled the mRNA expression of eight TLRs (TLR1-4 and TLR6-
9) in a cohort of 149 patients with MDS, and found increased
expression of TLR2 and its binding partners, TLR1 and TLR6, in
the CD34+ cells of these patients compared to healthy controls.
Notably, they showed that TLR2 expression was highest in the
lower-risk risk patients, correlating with better overall survival,
and conversely, TLR6 expression was highest in the higher-risk
patients. Zeng et al. (70) similarly found that TLR2 was more
highly expressed in the CD34+ cells of patients with lower-risk
MDS compared to healthy controls or to patients with high-
risk disease, and they noted that TLR2 expression correlated
with increased apoptosis. Further, they showed that TLR2
agonist-associated CD34+ cell death wasmediated by β-arrestin1
upregulation and histone H4 acetylation via recruitment of
P300. β-arrestin1 mRNA levels and nuclear accumulation of
β-arrestin1 protein were significantly increased in the CD34+
cells of patients with low-risk disease compared to higher-
risk MDS or healthy controls, and inhibition of β-arrestin1 in
cultured CD34+ cells mitigated TLR2 agonist-induced cell death
(70). In a smaller series of 21 patients, Maratheftis et al. (68)
reported increased expression of TLR4 in the CD34+ cells of
patients with MDS, and this expression also correlated with
cell death. In addition to these TLRs, mRNA expression of the
downstreammediator of TLR signaling, MyD88, was found to be
increased in the CD34+ cells of patients with MDS compared to
healthy controls, and inhibition of MyD88 in cultured CD34+
cells of lower-risk patients led to increased erythroid colony
formation. Of note, like the TLRs, this expression associated with
disease status, with lower-risk patients displaying higher MyD88
expression than higher-risk patients (67).
Not only are the TLRs overexpressed in MDS, but multiple
genetic abnormalities and epigenetic events in MDS have been
found to contribute to enhanced sensitivity to TLR ligands. In
patients with deletions of 5q (del(5q) MDS), for example, loss
of a copy of the micro-RNAs mir-145 and miR-146a result in
activated TLR signaling. These micro-RNAs normally inhibit the
TLR signaling intermediates TIRAP (mir-145) and TRAF6 (mir-
146a), and knockdown of these miRs or enforced expression
of TRAF6 in mouse hematopoietic stem and progenitor
cells recapitulates some of the features of human del(5q)
MDS including elevated serum IL-6 levels, megakaryocytic
dysplasia, and progression to marrow failure or acute myeloid
leukemia (71). Enhanced TRAF6 activity in del(5q) MDS is
further exacerbated by haploinsufficiency for another 5q gene,
TRAF-interacting protein with forkhead-associated domain B
(TIFAB), which normally promotes TRAF6 degradation via a
lysosome-dependent mechanism (72). TRAF6, a ubiquitin ligase,
contributes to impaired hematopoiesis and bone marrow failure
via ubiquitination of the RNA-binding protein and auxiliary
splicing factor hnRNPA1. This modification of hnRNPA1 results
in alternative splicing and reduced expression of Arhgap1, an
inhibitor of the GTP-binding Rho family protein Cdc42, which
in turn leads to aberrant hematopoiesis (73). Very recently, Muto
et al. (74) showed that TRAF6- overexpressing HSPCs have a
competitive advantage over their normal counterparts in the face
of low-dose LPS (TLR4 ligand). This advantage is dependent
upon the expression of A20 and the activation of non-canonical
NF-κB signaling, suggesting that the mechanistic basis for the
clonal advantage of MDS HSPCs involves an adaptive response
to TLR stimulation with a shift from canonical to non-canonical
NF-κB signaling.
Additionally, spliceosome mutations (e.g., involving
spliceosome components such as SF3B1, U2AF1, and SRSF2),
which are common in MDS (75), have been found to confer
sensitivity to TLR ligands by promoting the production
of activating forms of components of the TLR signaling
pathways. For example, Smith et al. (76) found that the
expression of a longer isoform of IRAK4 (IRAK4-L), which is
associated with enhanced activation of NF-kB and leukemic
transformation, is mediated by mutant forms of the splicing
factor U2 small nuclear RNA auxiliary factor 1 (U2AF1).
Similarly, Alper et al. (77–79) showed that inhibition of
spliceosome genes reduces inflammatory cytokine production
in response to TLR agonists, and conversely, expression of
MDS-associated spliceosome mutations (involving splicing
factors U2AF1, SF3B1, or SRSF2) enhances NF-κB activity
and cytokine production by K562 myeloid leukemia cells
following TLR stimulation. Mechanistically, the spliceosome
mutations alter the splicing of genes that regulate TLR signaling
and promote NF-κB activation, including MAP3K7 and
CASP8 (77).
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In addition to increased expression of TLRs and components
of the TLR signaling pathways, as well as enhanced sensitivity
to TLR ligands in the HSPCs of patients with MDS, some of
the known TLR ligands are more abundant in the bone marrow
and/or serum of individuals with MDS compared to healthy
controls. High mobility group box 1 (HMGB1), for example, a
nuclear DAMP released upon cell death that stimulates TLR2
and TLR4, is increased in the serum of patients with MDS
(80). Kam et al. (81) recently reported that HMGB1 inhibition
in cultures of an MDS cell line or primary MDS CD34+ cells
with the small molecule sivelestat reduced cellular expansion and
colony forming ability in vitro, as well as engraftment of the
MDS-L cell line into NSG mice. Further, inhibition of HMGB1
resulted in enhanced cell death, with increased expression of
p53-upregulated modulator of apoptosis (PUMA) and activation
of caspase-3. Interestingly, this inhibition also reduced the
expression of TLRs themselves in MDS CD34+ cells, suggesting
that TLR stimulation may amplify its own expression in MDS.
Besides HMGB1, the TLR4 ligands S100A8 and S100A9
are elevated in the bone marrow and blood of MDS patients
compared to controls, with the highest levels specifically found
in patients with lower-risk disease (82, 83). S100A8 and S100A9
are members of the S100 family of calcium-binding proteins that
exist as heterodimers (known as calprotectin) or homodimers,
and are expressed constitutively by myeloid lineage cells (84, 85).
These endogenous DAMPS are passively released by necrotic
cells or actively secreted by activated immune cells (86), bind to
both TLR4 and the myeloid cell receptor CD33, and contribute
to the ineffective hematopoiesis in MDS via direct and indirect
effects on HSPCs (87). S100A8 and S100A9, in addition to
playing a direct role in promoting cell death in HSPCs in MDS,
as discussed further below, expand myeloid derived suppressor
cells (MDSCs) in the bone marrow of patients with MDS
through binding to CD33. MDSCs are CD33+ Lineage- HLA-
DR- immature myeloid cells, and their frequency is significantly
increased in patients with MDS compared to healthy controls
(88, 89). Supporting a role for MDSCs and S100A9 in the
pathogenesis of MDS, S100A9 transgenic mice that overexpress
this DAMP in hematopoietic cells display an accumulation
of MDSCs with age, and develop progressive multilineage
cytopenias and dysplasias characteristic of human MDS (88).
MDSCs, which are typically distinct from the malignant clone
in MDS, contribute to the suppression of normal hematopoiesis
via the production of cytokines such as IL-10 and transforming
growth factor beta (TGFβ) (89). In addition, MDSCs can exert a
direct suppressive effect on the growth of erythroid and myeloid
progenitor cells in vitro (88), and very recent data from Cheng
et al. showed that the immune checkpoint receptor programmed
cell death protein-1 (PD-1) and its ligand programmed cell
death-ligand 1 (PD-L1) are upregulated in response to S100A9
signaling and contribute to MDSC-induced HSPC death in
MDS (90). Activated MDSCs secrete more S100A8 and S100A9
(91), thus supporting autocrine and paracrine TLR and CD33
stimulation and promoting further expansion of MSDCs and
inflammatory cytokine production.
Together, the above studies clearly establish enhanced TLR
signaling as a common feature ofMDS, particularly in the context
of lower-risk disease. The role of this enhanced TLR signaling
in the pathogenesis of the disease remains somewhat unclear,
however, and additional studies are necessary to fully elucidate
the contribution of TLR signaling to the initiation and promotion
of MDS. In addition, the etiology of increased TLR expression in
MDS is not well-understood, and further studies are warranted
to determine how TLR expression is regulated in both lower- and
higher-risk MDS HSPCs. TLR expression and signaling patterns
differ between low- and high-risk MDS, and the origin of these
differences and the roles of specific TLRs in different stages of
disease are not clear. Notably, TLR expression is induced in a
variety of cell types by inflammatory cytokines (92–94) and also
via positive feedback by TLR ligation itself (81), suggesting that
the inflammatory microenvironment may reinforce elevated TLR
expression and signaling. Finally, studies of TLR signaling in
MDS have largely focused on HSPCs, and, aside from MDSCs,
the expression of TLRs and contribution of TLR signaling in
populations outside of HSPCs to the pathogenesis of MDS is not
well-understood. One aspect of MDS pathogenesis that is clearly
influenced by TLR signaling is cell death, with accumulating data,
as discussed below, implicating this signaling in promoting the
intramedullary death of HSPCs in patients with lower-risk MDS.
TLR Signaling Promotes Cell Death in MDS
A hallmark of low-risk MDS is increased death of bone marrow
CD34+ cells (95–98), and multiple studies have implicated a
role for TLR signaling in this process. Both TLR2 and TLR4
signaling have been associated with cell death in MDS, and
recent studies demonstrate that TLR signaling promotes an
inflammatory form of programmed cell death termed pyroptosis
(11, 99, 100). Pyroptosis is mediated by the formation of
multiprotein complexes, known as the inflammasome, composed
of nucleotide-binding domain and leucine-rich repeat pattern-
recognition receptors (NLRs), most notably NOD-like receptor
pyrin domain-containing 3 (NLRP3) (101). NLRP3 assembly,
which is stimulated by DAMPs, leads to the recruitment of
the adaptor protein apoptosis-associated speck like protein
containing a CARD (PYCARD, also known as ASC), which then
form large helical fibrils that assemble into complexes referred to
as ASC specks (102–104). These specks function as a platform
for the binding and autoproteolytic activation of pro-caspase-
1, which then activates pro-IL-1β and pro-IL-18 as well as the
pore-forming protein gasdermin D (105–111). Membrane pores
created by activated gasdermin D lead to cation entry and cell
swelling, triggering pyroptotic cell death with the release of active
IL-1β, IL-18, and as well as ASC specks and other intracellular
proteins that contribute to local inflammation (112, 113).
TLR agonists such as S100A8 and S100A9, which bind
to TLR4 and CD33, stimulate inflammasome assembly, and
pyroptosis by enhancing the production of inflammasome
components, and proinflammatory cytokines such as pro-IL-
1β, and pro-IL-18. In addition, TLR agonists promote the
activation of NADPH oxidase to generate reactive oxygen
species (ROS), which contribute to inflammasome assembly
and inflammatory cytokine production (114). In a recent
study, Basiorka et al. (82) reported that markers of pyroptosis
(activated caspase-1, NLRP3, and ASC speck levels) were
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higher in the bone marrow mononuclear cells (BM-MNCs)
of patients with MDS compared to healthy controls, and
cell death was inhibited by shRNA-mediated knockdown of
NLRP3 or caspase- 1. Further, they showed that S100A9-
induced signaling activates NADPH oxidase, increasing ROS
and triggering pyroptosis and β-catenin activation in MDS
BM-MNCs, and inhibition of S100A9 using a decoy receptor
reduced transcriptional priming of pyroptosis-associated genes
(CASP1, IL-1B, IL-18, and NLRP3) and improved the colony-
forming capacity of BM-MNCs from patients with MDS. In
a follow up survey of 177 patients with MDS (115), Basiorka
et al. quantified ASC specks by flow cytometry and found
the mean percentage of peripheral blood plasma-derived ASC
specks to be significantly higher than in 29 age-matched
healthy controls (115). These findings were validated in an
additional cohort of 133 patients and 31 healthy controls,
and they found that ASC speck percentage correlated with
lower-risk disease as well as with S100A8 and S100A9 plasma
levels. These data support the idea that pyroptosis is a
prominent form of cell death in MDS, with TLR signaling-
particularly stimulation via S100A8 and S100A9- contributing to
this process.
Further implicating TLR signaling in the promotion of
pyroptotic cell death in MDS, we recently reported that loss
of TLR2 or MyD88 in the NUP98-HOXD13 (NHD13) mouse
model of MDS led to a reduction in premalignant cell death
andmore rapid leukemic transformation (116). Similar to human
MDS, the NHD13 mice (expressing the NUP98-HOXD13 fusion
from the hematopoietic Vav-1 promoter) display cytopenias,
bone marrow dysplasia, and increased HSPC cell death, and
the mice die of acute leukemia (predominately myeloid) or
bone marrow failure by about a year of life (117). Compared
to NHD13 mice; NHD13; Tlr2−/− and NHD13; MyD88−/−
mice have reduced survival and accelerated leukemogenesis,
and mechanistic evaluations showed that loss of TLR signaling
was associated with a reduction in activated caspase-1 and
decreased cell death of premalignant HSPCs. Furthermore,
we noted that while young adult NHD13 mice displayed
increased surface TLR2 expression on their bone marrow HSPCs
compared to WT littermates, this expression was markedly
reduced (or absent) on leukemic blasts, suggesting that TLR2 is
downregulated at some point during the transformation process.
This finding is consistent with the human studies showing
higher expression of TLR2 in low-risk patients compared to
FIGURE 1 | TLR signaling is enhanced in MDS. In low-risk MDS, TLR signaling is enhanced via increased expression of TLRs, increased abundance of DAMPs such
as HMGB1 and S100A8/A9, and increased sensitivity to TLR ligands. S100A8/A9 binds to TLR4 and CD33, stimulating inflammasome assembly and pyroptotic cell
death by promoting the production of inflammasome components, ROS, and proinflammatory cytokines such as IL-1β and IL-18. In addition, S100A8/A9 binding to
CD33 expands MDSCs, which contribute to the suppression of normal hematopoiesis via the production of cytokines such as IL-10 and TGFβ. Activated MDSCs
secrete more S100A8 and S100A9, thereby promoting autocrine and paracrine TLR and CD33 signaling and stimulating further expansion of MSDCs and
inflammatory cytokine production. In high-risk MDS and AML, endogenous DAMPs and MDSCs are less abundant than in low-risk MDS, and there is less cell death.
Also, expression levels of TLR2, TLR4, and MyD88 are lower than in low-risk MDS. On the other hand, expression of an activating form of IRAK4 is associated with
high-risk MDS and leukemic transformation.
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high-risk (69, 70), as well as the correlation between TLR2
expression and cell death (70). Together, these data suggest
that while TLR2 signaling may contribute to the death of
HSPCs- a prominent feature of low-risk disease- it may also
serve a protective role against the accumulation of premalignant
cells and ultimate transformation. It is presently unclear
what regulates TLR2 expression in the HSPCs of patients
with MDS, and how this expression is reduced in higher-
risk patients.
Targeting TLR Signaling in the Treatment
of MDS
As discussed above, multiple components of the TLR signaling
pathway are upregulated in MDS, which has prompted
enthusiasm for targeting this signaling therapeutically. A TLR2
inhibitory antibody (Tomaralimab, Opsona Therapeutics) has
now been trialed as second-line therapy for patients with lower-
risk MDS (NCT02363491) (118). In addition, a phase I study
of a novel small molecule inhibitor of IRAK4 is currently
enrolling patients with high-riskMDS and AML (NCT04278768)
(119). Of note, enhanced TLR signaling is largely specific
to lower-risk MDS, where it promotes cell death, and the
effects of TLR signaling and the potential consequences of
its inhibition in higher-risk patients is not clear. That said,
certain elements of TLR signaling, such as expression of the
activating form of IRAK4 (IRAK4-L), are more characteristic
of high-risk MDS and progression to AML (76). Thus, not all
TLR signaling may be equal in MDS, with certain TLRs or
signaling components conferring different effects in different
disease contexts. These nuances regarding the role of TLR
signaling in both lower- and higher-risk MDS warrant further
study, and will help inform which patients might benefit
from modulation of TLR signaling, as well as identify the
components of this signaling pathway that represent the best
therapeutic targets.
Finally, while inhibition of TLR signaling has been the general
strategy for MDS, multiple studies suggest that stimulation of
this signaling may have therapeutic efficacy in AML, with TLR
agonists promoting the death and differentiation of myeloid
blasts (120–126). For example, S100A9 was found to induce cell
differentiation and growth arrest and prolong survival in a mouse
model of AML, and mechanistic studies showed that S100A9
induced this differentiation in AML cells via S100A9 binding
to TLR4 and activation of ERK1/2 and JNK signaling pathways
(125). Eriksson et al. (124) demonstrated that the TLR1/2 agonist
PAM3CSK4 induces p38-dependent apoptosis and NF-κB-
dependent differentiation of both murine and primary human
AML cells (124). Similarly, Ignatz-Hoover et al. (123) found
that TLR8 activation promotes AML differentiation and growth
inhibition in aMyD88 and p38-dependent fashion. Finally, TLR7
stimulation with imiquimod inhibited proliferation, upregulated
myeloid differentiation markers, and induced apoptosis in AML
cell lines (127).
In addition to directly promoting AML cell death and
differentiation, TLR agonists have also been considered for
use as anti-tumor agents for their indirect effects on leukemia
cells via promotion of the natural immune response to
these cells (128–130). For example, incubation of primary
AML cells with the TLR7/8 agonist R-848 led to increased
expression of MHC molecules, proinflammatory cytokine
production, and enhanced stimulation of allogeneic NK,
NKT, and T cells (128), and loading of AML cells with
the TLR3 agonist polyriboinosinic polyribocytidylic acid
[poly(I:C)] led to increased MHC expression, apoptosis, and
proinflammatory cytokine production, and enhanced the
maturation and activation of dendritic cells after their uptake
(125, 128, 129). Thus, the role of TLR signaling in MDS appears
to be context-dependent, and the clinical application of agents
that modulate TLR signaling should take into account the
disease status, likelihood of progression to AML, and the
particular components of the TLR signaling machinery that
are activated in a given patient. Finally, TLR-targeted therapies
alone may not eradicate MDS, but may be a useful component
of therapy to optimize normal blood cell production and slow
disease progression.
SUMMARY AND FUTURE DIRECTIONS
Enhanced innate immune signaling, and in particular TLR
signaling, is a common feature of MDS. The etiology of
this TLR signaling upregulation is multifactorial, involving
increased expression of TLRs and downstream signaling
components, enhanced sensitivity to TLR stimulation, and
increased availability of TLR ligands in the bone marrow
and blood of patients with MDS. In many cases, the
mechanism of TLR upregulation is not clear. Furthermore,
TLR expression differs between low- and high-risk patients,
suggesting that the role of TLR signaling may change
as MDS disease progresses (Figure 1). Further studies are
necessary to determine the contribution of specific TLRs to
disease pathogenesis, as well as to understand how their
expression is regulated in both lower- and higher-risk MDS.
Finally, the contribution of TLR signaling in cell type(s)
aside from CD34+ HSPCs to the ineffective hematopoiesis
and/or leukemic progression is not well-understood, and a
more comprehensive study of how TLR signaling is altered
throughout the bone marrow in patients with MDS is warranted.
Ultimately, these studies will help to inform the development
of improved TLR signaling-targeted therapies for the treatment
of MDS.
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